<DOC>
	<DOCNO>NCT01388595</DOCNO>
	<brief_summary>Allergic rhinitis diagnose global health problem affect 25 % population worldwide . It report one 10 common cause attendance primary care clinic . It clinically define symptomatic disorder nose induce IgE mediate inflammation follow allergen exposure membrane line nose characterize varying combination nasal symptom include sneezing , nasal blockage , rhinorrhoea itching . Intra nasal corticosteroid form cornerstone anti-inflammatory therapy allergic rhinitis increase interest role intranasal beta 2 agonist management allergic rhinitis . The question therefore arise whether salmeterol exhibit synergistic activity nose term potentiate steroid response fluticasone .</brief_summary>
	<brief_title>Fluticasone Salmeterol Allergic Rhinitis</brief_title>
	<detailed_description>In vitro ex vitro data suggest salmeterol may exhibit ligand independent activation glucocorticoid receptor , might result potentiation fluticasone salmeterol give combination . Although evidence synergy report fluticasone salmeterol combination nose allergen challenge , data available nasal AMP challenge nose . This study compare single long term dose effect intranasal fluticasone alone , salmeterol alone fluticasone salmeterol combination nasal AMP challenge persistent allergic rhinitis sufferer . Nasal corticosteroid , leukotriene receptor antagonist anti histamine stop one week start randomize treatment run phase wash period . Intransal sodium cromoglycate spray provide rescue use throughout study witheld least twenty four hour challenge . Nasal AMP challenge perform baseline , run-in washout , 12 hour first last evening dose study medication . A Zerostat Antistatic spacer ( Cipla , Mumbai , India ) use administer randomized treatment , adapt nasal olive intranasal use instead conventional mouthpiece . The randomized treatment give daily night time follow : placebo hydrofluoroalkane , 2 puff ( Cipla , Mumbai , India ) salmeterol-hydrofluoroalkane , 2 puff 25 g ( Serevent Evohaler Allen Hanburys , Middlesex , United Kingdom ) fluticasone- salmeterol hydrofluoroalkane , 2 puff 250/25 g ( Seretide Evohaler , Allen Hanburys ) fluticasone-hydrofluoroalkane,2 puff 250 g ( Flixotide Evohaler , Allen Hanburys ) . The double-blind randomization process computer generate www.randomization.com . Trial drug randomization perform direct supervision clinical trial pharmacist Ninewells University Hospital . Active fluticasone , salmeterol , fluticasone-salmeterol combination procure GlaxoSmithKline ( Allen Hanburys ) clinical trial pharmacy match placebo provide Cipla . Following Informed Consent screen visit , participant provide randomize , label treatment pack single inhaler , either active placebo study treatment visit . Blinding patient investigator ensure use identical colored actuator treatment label active placebo canister trial-specific label . Measurements make 12 hour first last dose randomize treatment . At initial screening , nasal endoscopy perform exclude significant nasal polyp disease ( great grade 1 ) , concha bullosa , septal deviation . A Niox Flex nitric oxide analyzer ( Aerocrine AB , Solna , Sweden ) use measure nasal nitric oxide . The standard aspiration technique recommend American Thoracic Society/European Respiratory Society guideline use unilateral , nasal olive , breath-holding , velum closure . For nasal AMP challenge , PNIF measure every 5 minute 60 minute 4 squirt 0.1 mL per actuation nostril 400 mg/mL AMP ( ie , 320-mg total dose ) deliver nose . The maximum decrease PNIF measure use In-check Nasal Inspiratory Flow Meter ( Clement Clarke International Ltd , Harlow , United Kingdom ) . It show measure PNIF ( PEAK NASAL INSPIRATORY FLOW ) response sensitive measuring nasal airway resistance also reproducible.PNIF correlate well vs symptoms response treatment allergic rhinitis patient show minimal clinically important difference 5 L/min . At screening , patient instruct correct technique particular attention horizontal position meter , close mouth maximal peak nasal inspiratory effort , adequate mask seal around mouth nose . Nasal impulse oscillometry measurement nasal airway resistance 5 Hz perform use Jaeger MasterScreen impulse oscillometry system ( Erich Jaeger , Hoechberg , Germany ) . The total nasal symptom 4 ( TNS4 ) score record visit , total score 12 sum 4 separate domain nasal blockage , run , itch , sneeze , rat 0 3 . The Juniper Mini Rhinoconjunctivitis Quality Life Questionnaire ( Mini-RQLQ ) complete participant immediately week randomize treatment . The global RQLQ mean 5 individual domain , individual domain score 0 6 . Serum eosinophilic cationic protein measure use enzyme-linked immunoassay technique ( UniCAP ; Sweden Diagnostics UK Ltd , Milton Keyes , United Kingdom ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Persistent allergic rhinitis without asthma . 2 . Atopy least 1 allergen SPT . 3 . ≥ 20 % drop PNIF follow nasal AMP challenge 4 . Male female age 1865 5 . Informed Consent 6 . Ability comply protocol 1 . Severe allergic rhinitis define symptom significantly impair day day activity QOL questionnaire . 2 . Nasal Polyposis grade 2/3 , deviate nasal septum ≥ 50 % 3 . PNIF &lt; 60 litres/min 4 . The use oral corticosteroid within last 3 month . 5 . Recent respiratory tract / sinus infection ( 2 month ) . 6 . Significant concomitant respiratory disease COPD , CF , ABPA , bronchiectasis active pulmonary tuberculosis . 7 . Any clinically significant medical condition unstable angina , acute myocardial infarction precede 3 month , recent TIA/ CVA , may endanger health safety participant , jeopardise protocol . 8 . Any significant abnormal laboratory result deem investigator 9 . Pregnancy , plan pregnancy lactation 10 . Known suspected contraindication IMP 's 11 . Concomitant use medicine ( prescribe , counter herbal ) may interfere trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>